Bookmark Kaumudi Online  Bookmark this site  Editor@Kaumudi  |  Marketing  Print Advt rates  |  Calendar 2018        Go!    
June 21, Thursday 2018 2:05 AM       

       HEADLINES: Cheriyan Philip to be Mission coordinator                                              Chengannur by-election: Congress man arrested for spreading controversial phone message                                              Agri budget to double farm income by 2022: PM Modi                                              Governor's rule imposed in J-K                                              18K banks, post offices have Aadhaar facility: UIDAI                                              Swaraj discusses bilateral trade, investment with Luxembourg PM                                              India dismisses UN report branding terrorists as "leaders"                                              China 'colonising' terror-supporting Pak - EFSAS                                              My hardest day in cricket: Paine post England drubbing                                              Kaumudi Facebook
       SINGAPORE Next Article: Singapore Airlines among top 20 safest airlines: Airline ratings website  
       A decade-old cancer drug that was deemed too weak for use has drawn interest
         Posted on :07:33:14 Jan 8, 2016
       Last edited on:07:33:14 Jan 8, 2016
         Tags: sg
SINGAPORE: A decade-old cancer drug that was deemed too weak for use has drawn interest from the scientific community in recent years after the discovery of a more potent version of it. While scientists in Europe and the United States are focused on testing the drug for blood cancer and prostate cancer treatments, researchers here are suggesting that the PRIMA-1met drug could be used to treat colorectal cancer — the most common cancer in Singapore. The team at the National University of Singapore (NUS) has found the drug to be effective in inhibiting the growth of colorectal cancer cells. When administered, the researchers found that the drug increases the quantity of a protein called Noxa in the patient’s body, which in turn helps to reactivate the cell-killing processes of a mutated p53 gene. This will return the gene to its active form, which naturally suppresses cancerous growth. The drug could therefore help in containing malignant tumour growth and render chemotherapy treatment more effective. “In a way, the cancer cells self-implode because the exposure to the drug activates the mechanism in the cancer cell that actually kill the cells on its own,” said Professor Chng Wee Joo, who led the research. The study, which was supported by grants from the National Research Foundation, Ministry of Education and the National Medical Research Council, was published in the journal Oncotarget. Breakthroughs in the field of colorectal cancer treatment have been sparse in Europe and the US, where screening programmes have better take-up rates, but Dr Chng noted that the problem is a significant one in Singapore, where patients are often diagnosed late. Dr Chng, who is also the deputy director and senior principal investigator at Cancer Science Institute of Singapore, said that 50 per cent of patients who die from colorectal cancer in Singapore have this p53 mutation, which is usually found in later-stage patients. Among newly-diagnosed patients here, 20 to 30 per cent have the p53 mutation, he added. Others have a higher likelihood of developing p53 mutation when their condition worsens. In its next steps, the NUS team plans to test if the combination of PRIMA-1met with anti-cancer drugs such as Fluorouracil and Oxaliplatin, commonly used for the treatment of colorectal cancer, will optimise the results of chemotherapy. The team is also reaching out to pharmaceutical companies to conduct a clinical trial. Finding out the drug’s appropriate dosage range and potential side effects are main concerns at this stage. From 2010 to 2014, there were 9,324 new colorectal cancer cases in Singapore, statistics from the Singapore Cancer Registry show. The disease had the second-highest cancer mortality rate among men and third-highest among women. There were 3,726 colorectal cancer deaths during this period. Deaths from colorectal cancer have seen a steady decrease since 1999 due to advances in treatment, such as adjuvant therapy that combines chemotherapy, radiotherapy, and total mesorectal excision. Read the original TODAY report here. -TODAY/kk
Next Article: Singapore Airlines among top 20 safest airlines: Airline ratings website
Esplanade Presents | Kalaa Utsavam – Indian Festival of Arts / 2017  
Bali Volcano  
Soorya Singapore  
Swathi Thirunal Festival  
H7The New President of Singapore  
Halimah Yacob elected as New President of Sigapore  
All races must have the chance to be elected President: Ong Ye Kung  
one of Singapore’s greatest sons  
Vigil guards to be mounted for S R Nathan's Lying-in-State  
Schooling wins gold in 100m butterfly final  
Vending machine cafe opens in HDB estate  
Shobana in Singapore  
Former President S R Nathan suffers stroke  
Singapore Airlines says Q1 net profit nearly triples  
Indian Heritage Centre , Singapore  
Dancing Drums - Trance on 2nd Sept at NUS UCC hall.  
Pravasi Express Nite- 2016  
Fully-electric taxis to ply Singapore's roads from September  
Kaavya Sopaanam launched  
Singapore Malayalee Literary Forum (SMLF) launches Kavya Sopanam  
Pravasi Express Nite 2016 on 6th August  
Naataka Mela by Singapore Malayalee Association  
Productivity initiatives at Changi Airport to reduce reliance on manpower  
Universal Studios Singapore top amusement park in Asia: Tripadvisor  
NUS, NTU come out tops in Asia university ranking  
Do you think electric bus will be a success in Kerala?
No opinion
Home Kerala India World Business Sports Sci&Tech Education Automobile CityNews Movies Environment Letters 
© Copyright keralakaumudi Online 2011  |  Reproduction in whole or in part without written permission is prohibited.
Head Office Address: Kaumudi Buildings, Pettah P.O, Trivandrum - 695024, India.
Online queries talk to Deepu Sasidharan, + 91 98472 38959 or Email deepu[at]
Customer Service -Advertisement Disclaimer Statement   |  Copyright Policy